Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

被引：9

作者：

Kim, Hyung L. ^{[1
]}

Mayerson, Eddie ^{[2
]}

Lara, Primo N. ^{[3
]}

Messing, Edward ^{[4
]}

Tangen, Cathy ^{[2
]}

Shuch, Brian M. ^{[5
]}

Vaishampayan, Ulka ^{[6
]}

机构：

[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Univ Calif Davis, Sacramento, CA 95817 USA

[4] Univ Rochester, Rochester, NY USA

[5] Univ Calif Los Angeless, Los Angeles, CA USA

[6] Wayne State Univ, Detroit, MI USA

来源：

EUROPEAN UROLOGY FOCUS | 2019年 / 5卷 / 06期

关键词：

cytoreductive nephrectomy; metastatic renal cell carcinoma; immunotherapy;

D O I：

10.1016/j.euf.2019.05.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Trials SWOG 8949 and EORTC 30947 had the same eligibility criteria and established the role of cytoreductive nephrectomy for metastatic renal cell carcinoma. The more recently published CARMENA trial calls into question the need for cytoreductive nephrectomy. A systematic comparison of CARMENA and SWOG 8949 suggests that cytoreductive nephrectomy may be beneficial for patients receiving immunotherapy but not targeted therapy. The approval of immune checkpoint inhibitors for previously untreated metastatic renal cell carcinoma underlines the need for another randomized phase 3 trial of cytoreductive nephrectomy for patients receiving powerful modern immunotherapies. (C) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

引用

页码：927 / 929

页数：3

共 5 条

[1] Bex A, 2019, JAMA ONCOL, V5, P164, DOI 10.1001/jamaoncol.2018.5543
[2] Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
Flanigan, RC
Salmon, SE
Blumenstein, BA
Bearman, SI
Roy, V
McGrath, PC
Caton, JR
Munshi, N
Crawford, ED
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) : 1655 - 1659
[3] Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Mejean, A.
Ravaud, A.
Thezenas, S.
Colas, S.
Beauval, J. -B.
Bensalah, K.
Geoffrois, L.
Thiery-Vuillemin, A.
Cormier, L.
Lang, H.
Guy, L.
Gravis, G.
Rolland, F.
Linassier, C.
Lechevallier, E.
Beisland, C.
Aitchison, M.
Oudard, S.
Patard, J. -J.
Theodore, C.
Chevreau, C.
Laguerre, B.
Hubert, J.
Gross-Goupil, M.
Bernhard, J. -C.
Albiges, L.
Timsit, M. -O.
Lebret, T.
Escudier, B.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05) : 417 - 427
[4] Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
Mickisch, GHJ
Garin, A
van Poppel, H
de Prijck, L
Sylvester, R
[J]. LANCET, 2001, 358 (9286) : 966 - 970
[5] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J.
Tannir, N. M.
McDermott, D. F.
Frontera, O. Aren
Melichar, B.
Choueiri, T. K.
Plimack, Elizabeth R.
Barthelemy, P.
Porta, C.
George, S.
Powles, T.
Donskov, F.
Neiman, V.
Kollmannsberger, C. K.
Salman, P.
Gurney, H.
Hawkins, R.
Ravaud, A.
Grimm, M. -O.
Bracarda, S.
Barrios, C. H.
Tomita, Y.
Castellano, D.
Rini, B. I.
Chen, A. C.
Mekan, S.
McHenry, M. B.
Wind-Rotolo, M.
Doan, J.
Sharma, P.
Hammers, H. J.
Escudier, B.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) : 1277 - 1290

← 1 →